KOL Insight: Psoriasis [2020]

Maximum Purchase:
1 unit
Publication Date:
August 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Psoriasis [2020]

Anti-TNF's grip on the psoriasis market will come under pressure due to biosimilar competition and the arrival of new anti-IL17 and anti-IL23 therapies. What does the future hold for anti-TNF products such as Abbvie's Humira, and how do KOLs rate anti-IL23 products such as AbbVie/Boehringer Ingelheim's Skyrizi and Jansen Biotech's Tremfya? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • What benefits do KOLs see for Eli Lilly's Taltz over Novartis' Cosentyx in the anti-IL17 class?
  • How might biosimilar Stelara successfully defend market share from new anti-IL17/23 therapies?
  • What safety issues are concerning KOLs when using anti-IL17 therapies and how is it influencing practice?
  • What clinical advantages do KOLs identify for Amgen's oral therapy Otezla and will BMS' pipeline tyk2 inhibitor BMS-986165 have the potential to compete?
  • In which niche setting do KOLs see Boehringer Ingelheim's pipeline anti-IL36 monoclonal antibody, spesolimab, delivering value?

Examples of Therapies Covered

Stelara Tremfya
Cosentyx Otezla
Mirikizumab Bimekizumab
Piclidenoson Spesolimab
Siliq BMS-986165

Partial List of Participating KOLs

  • Professor of Dermatology
    Wake Forest Baptist Medical Center, Winston-Salem, NC.
  • Professor of Medicine
    University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Associate Clinical Professor of Dermatology
    Mount Sinai Hospital, New York, NY.
  • Professor of Dermatology
    Humanitas University, Pieve Emanuele, Milan, Italy.
  • Professor of Dermatology
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Director of the Department of Dermatology
    Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner